
M. González-Sabin, a,∗ S. Mallo-García, a E. Rodríguez-Díaz, a P. Gonzalvo-Rodríguezb
a Servicio de Dermatología, Hospital de Cabueñes, Gijón, Asturias, Spain
b Servicio de Anatomía Patológica, Hospital de Cabueñes, Gijón, Asturias, Spain
∗ Corresponding author. E-mail address: martagonzalezsabin@gmail.com (M. González-Sabin).

The coexistence of morphea and psoriasis is a rare finding in routine clinical practice. To date, 19 cases have been described in the literature (Table 1). Nevertheless, psoriasis is the autoimmune disease most frequently associated with morphea, accounting for 11.6% of cases in which an immune-mediated disease occurs in conjunction with morphea. The small number of case reports and the lack of knowledge about the pathophysiologic mechanisms of both entities make it difficult to understand this phenomenon. Nevertheless, we have developed several hypotheses.

First, our patient could have developed morphea concomitantly with psoriasis due to a common immunologic basis of the 2 entities. Multiple helper T (Th1) cell differentiation pathways besides those mentioned in this article have been described; 3 such pathways are of special interest in our case. The Th1 pathway and its associated interleukins (IL)—IL-2, IL-12, and interferon (IFN) γ—regulate cellular immunity and are associated with conditions such as psoriasis, inflammatory bowel disease, and graft-versus-host disease. The Th17 pathway—which is associated with IL-4, IL-5, and IL-13—is involved in humoral immunity and is, to date, the main pathway known to be involved in morphea. A third, recently described pathway—Th17, associated with IL-17, IL-22, and IL-23—is believed to play a more important role in immune-mediated diseases. This pathway appears to interact with the 2 pathways mentioned above. Several authors have argued that dysregulation of these pathways could be responsible for the coexistence of morphea and psoriasis in the same patient. The immunologic environment of psoriasis, dominated by the Th17 pathway, could mask manifestations of sclerosing diseases such as morphea, which are dominated by Th1. Along these lines, Bezalel et al. reported the case of a patient who developed plaques of morphea while receiving IFN treatment for multiple sclerosis. The authors concluded that IFN-induced activation of

Morphea in a Patient With Psoriasis on Treatment With Ustekinumab: Comorbidty or Adverse Effect?7

Morphea en una paciente con psoriasis en tratamiento con ustekinumab: ¿coexistencia o efecto adverso?

To the Editor:

We report the case of a 63-year-old woman with a history of pustular and plaque psoriasis that had first appeared 4 years earlier. The patient had previously received treatment with topical clobetasol, calcipotriene-betamethasone, and oral acitretin at a dose of 25 mg/d, as well as narrowband UV-B phototherapy. Because of the persistence of the lesions, we decided to initiate systemic therapy with ustekinumab. At a follow-up appointment 6 months after the start of biologic therapy, the psoriasis had improved. However, on the back of both legs, several hard, pearly plaques with violaceous edges had appeared in lightened areas of older psoriasis plaques (Figures 1A and 1B). Localized morphea was clinically suspected. A biopsy specimen was taken from one of the lesions and histologic examination resulted in a diagnosis of morphea (Figure 1C).

Please cite this article as: Corral Magaña O. Morphea en una paciente con psoriasis en tratamiento con ustekinumab: ¿coexistencia o efecto adverso?. Actas Dermosifiliogr. 2017;108:486–488.
the Th2/IL-4 pathway could have triggered the appearance of morphea-like lesions.

The immunogenic hypothesis is also supported by the fact that antinuclear antibody positivity is more prevalent in patients with both psoriasis and morphea.4 Taking into account the information outlined above, it is also possible that the introduction of ustekinumab, an anti-IL-12/23 monoclonal IgG1 antibody, could have blocked the Th1 signaling pathway, leading to increased expression of Th2 and consequently the formation of morphea plaques in a predisposed patient. Therefore, we cannot rule out the possibility that the development of morphea in our patient was an adverse effect of ustekinumab. This drug was approved by the US Food and Drug Administration in June 2008. We have found no reports to date of ustekinumab being associated with the development of morphea. However, an association between etanercept and morphea plaques—extending from the injection site—has been reported in a patient with psoriasis.6

Finally, in a predisposed patient, the psoriasis itself could have triggered the morphea—an example of the Wolf isotopic response.

In conclusion, we cannot rule out any of the 3 hypotheses: immunologic, pharmacologic, and the Wolf isotopic response. Likewise, it is impossible to know whether the morphea was previously present under the psoriasis plaques. Nevertheless, we believe that the 3 hypotheses are not mutually exclusive; the interaction of the drug with an altered immune system could have caused the development of morphea in our patient. Reports of similar new cases and a better understanding of the pathophysiology mechanisms of both diseases could shed light on this enigma.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

---

**Table 1** Cases Reported in Indexed Journals of Psoriasis and Morphea in the Same Patient.

<table>
<thead>
<tr>
<th>Case No.</th>
<th>Age, ya</th>
<th>Sex</th>
<th>Initial Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>1-5</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>65</td>
<td>M</td>
<td>Morphea</td>
</tr>
<tr>
<td>7</td>
<td>62</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>8</td>
<td>24</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>9-16</td>
<td>—</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>17-18</td>
<td>45</td>
<td>F</td>
<td>Psoriasis</td>
</tr>
<tr>
<td>19</td>
<td>45</td>
<td>F</td>
<td>Morphea</td>
</tr>
</tbody>
</table>

Abbreviations: M, male; F, female.

a Age at first diagnosis.
b Patient was being treated with etanercept at the time of the diagnosis of morphea.

---

**Figure 1** Clinical and histologic images of the patient. A, Hard, pearly plaques with violaceous edges (lilac ring) underneath older psoriasis plaques on the lower limbs. B, More detailed image showing the coexistence of morphea plaques and erythematous plaques with a psoriasiform appearance. C, Densely packed collagen bands in the deep reticular dermis, parallel to the dermoepidermal junction (hematoxylin-eosin, original magnification × 10).
Chondrocutaneous Graft for Reconstruction of the Ala Nasi

Reconstrucción del ala nasal mediante injerto condrocutáneo

To the Editor:

The external nose is a sun-exposed area with a high incidence of skin tumors. These tumors are treated surgically in the majority of cases. The nasal ala, composed of mucosa, cartilage, and skin, is an anatomically complex structure and its reconstruction is thus also complex. During reconstruction of defects of the ala we must take into account the size and thickness of the defect, the color and texture of the surrounding skin, symmetry with the contralateral ala, and the condition of the perilesional tissues. We must also evaluate the characteristics of possible donor sites and the patient’s past history. The main objective is to preserve the valve function and the cosmetic appearance of the external nose.

We describe the case of a 77-year-old woman with a complex past history. She presented biopsy-confirmed recurrence of basal cell carcinoma on the right nasal ala.

The tumor recurrence (Fig. 1A) was treated using Mohs micrographic surgery (Fig. 1B), with complete excision being achieved in a single stage. This surgery left a full-thickness defect of the nasal ala measuring 0.8 x 1 cm, affecting the free border of the ala.

To repair the defect we decided to use a composite chondrocutaneous graft from the base of the helix. In this situation, the ideal donor site is the auricle of the ear not only for color and texture, but also because the anterior region of the helix permits simple graft extraction and direct closure. The graft obtained presents cartilage between 2 skin surfaces. The cartilage provides mechanical stability and form to the graft and to the nasal ala, preventing collapse of the graft with respiratory movements. Additionally, the cartilage prevents scar retraction and secondarily preserves valve function.

In our patient, we first designed and excised a V-shaped en bloc graft from the base of the helix, 1 mm larger than the defect (Fig. 1C). The resulting defect in the helix was closed using interrupted sutures (Fig. 2B).

To fix the graft to the receptor site, we first sutured the tissue to the internal surface of the nasal ala using an absorbable 5/0 suture. The graft was then immobilized using a nasal pack. Finally, the skin of the external surface was sutured with 5/0 silk (Fig. 2A).

The use of a composite graft from the auricle of the ear to reconstruct the external nose was first described by Konig in 1902. Its main advantages are that surgery can be performed in a single stage, with an en bloc graft, allowing the procedure to be completed in a single operation.

Factors that can reduce chondrocutaneous graft survival include smoking, alteration of the vascular supply by previous radiotherapy, the presence of scars, diabetes, and severe arteriosclerosis. Large grafts have high metabolic demands, reducing their likelihood of survival. Previous reports have therefore recommended a maximum diameter of 10 mm for chondrocutaneous grafts. However, good results have been reported with grafts up to 10 x 18 mm.

References


O. Corral Magaña, A. Escalas Taberner,* M.M. Escudero Góngora, A. Giacaman Contreras Servicio de Dermatología, Hospital Universitario Son Espases, Palma de Mallorca, Islas Baleares, Spain

* Corresponding author.
E-mail address: jetpalma@hotmail.com

(1578-2190/ © 2016 Elsevier España, S.L.U. and AEDV. All rights reserved.)